An Outline For a Cost-Effectiveness Analysis of a Drug For Patients With Alzheimer's Disease

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.13, Iss.1 Part 2, 1998-01, pp. : 21-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Health Utilities in Alzheimers Disease and Implications for Cost-Effectiveness Analysis

By Neumann Peter J.

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 537-541

Adis International

Access to resources Recommend Favorite

Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis

By Green Colin

PharmacoEconomics, Vol. 25, Iss. 9, 2007-01 ,pp. : 735-750

Adis International

Access to resources Recommend Favorite

A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer's Disease

By Kirby Joanna Green Colin Loveman Emma Clegg Andrew Picot Joanna Takeda Andrea Payne Elizabeth

Drugs & Aging, Vol. 23, Iss. 3, 2006-01 ,pp. : 227-240

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Treatment Options in Patients with Alzheimer's Disease: A Systematic Review of Cost-Effectiveness Analyses

By Pouryamout Laura

Drugs, Vol. 72, Iss. 6, 2012-04 ,pp. : 789-802

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis: A Case for Excluding Dialysis Costs

By Grima Daniel T.

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 981-989

Adis International

Access to resources Recommend Favorite